Last reviewed · How we verify
HCTZ monotherapy
HCTZ (hydrochlorothiazide) is a thiazide diuretic that reduces blood pressure by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the kidney.
HCTZ (hydrochlorothiazide) is a thiazide diuretic that reduces blood pressure by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the kidney. Used for Hypertension, Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease.
At a glance
| Generic name | HCTZ monotherapy |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Thiazide diuretic |
| Target | Sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
HCTZ blocks the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, leading to increased urinary sodium and water excretion. This reduces blood volume and total peripheral resistance, thereby lowering blood pressure. It is commonly used as monotherapy or in combination with other antihypertensive agents for hypertension management.
Approved indications
- Hypertension
- Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease
Common side effects
- Hypokalemia
- Hyperglycemia
- Hyperuricemia
- Hyponatremia
- Ototoxicity (at high doses)
- Photosensitivity
- Erectile dysfunction
Key clinical trials
- MK0954A-264 Filter Study (0954A-264)(COMPLETED) (PHASE3)
- A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327) (PHASE3)
- BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) (PHASE3)
- SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335) (PHASE3)
- VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil (PHASE3)
- Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension (PHASE3)
- Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302) (PHASE3)
- Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |